RE: Yet more tyk2 confirmation10 Mar 2021 21:41
Yes there was a comma a few words in. You would have one hell of a job narrating that sentence. Lungs would never be able to hold that much air.
Seriously, Sareum will be in communication with companies. They cannot divulge who they are in communication with. SP price would rocket and then collapse if discussions then stopped. This was told me by a solicitor a few years ago. He specialised in company law. Poor old bugger dead now from throat cancer.
Discussions take time. You have a company with a product and potential buyers. As a buyer you will buy a product to make a profit. Tyk2 is worth a considerable amount with the potential it has. However potential will be weighed against risk. A company will pay top notch if it says what it will do on the side of the tin. TYK2 still has risk of failure. We are fine so far with toxicology in immunotherapy and cancer. For the drug to be successful it must surpass the effectiveness of current treatments as well as have a higher safety profile, we do not want any black box warnings.
In addition there is an extremely high likely hood of it being fast tracked against Covid 19. This will place a significant/ astronomical increase in the SP should this be achieved.
Put yourself in a buyers position where management are accountable for purchasing or obtaining a licence for such a product. Do you negotiate on speculation and hence maintain a possibility of failure or do you hold out and see what the results are and if successful buy at the ' it does what it says on the side of the tin'?
From the sellers point of view ie Sareum do you nigh give it away for a few million and the likelyhood that the buyer will make billions on a probability that may be a nigh certainty of success, or hold however difficult that may be in the knowledge that should we progress to a certain stage with positive results it is worth considerably more putting the financial gain into the profits of shareholders and not the buyer?
We have interested parties of that there is no doubt. Discussions will be going ahead. I feel at the moment that the buyer wants it for next to nothing due to risk however small and Sareum will not play ball. A turning point will be granting of a fast track for Covid and hence not only the effectiveness in this disease but also the tolerability of TYk 2 with respect to treating cancers and immunotherapy. Yes we all get a bit p 155 ed off at times. There is nothing we can do to hurry it. The only downside I can see is being able to produce in sufficient quantities should the need be required.
Not as long as some but been here now nearly 9 years. The price has steadied around the 1.7 to 1.8p mark. I do no not see it changing much until news is released either good or bad. We wait news and results and so does any interested pharma.
Sierra, I am a little peeved with as no indication how or when they are going to proceed with SRA737.
Regards
Sign In
Follow the stocks
